Galmed Pharmaceuticals
GLMD
31 hedge funds and large institutions have $56.9M invested in Galmed Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
7% more funds holding
Funds holding: 29 → 31 (+2)
0% more ownership
Funds ownership: 0.02% → 0.03% (+0%)
7% less capital invested
Capital invested by funds: $61.1M → $56.9M (-$4.24M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $74K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$1.06M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$609K |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
+$557K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$413K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$503K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$330K |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$144K |
| 4 |
Goldman Sachs
New York
|
-$138K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$103K |
GLMD Hedge Fund Activity: Q2 2019 in Review
31 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2019, worth a combined $56.9M — down 6.9% from $61.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GLMD positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Ibex Investors, adding an estimated $1.06M. The largest seller was UBS O'Connor, exiting entirely with an estimated $503K sold.
- 31 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2019, up from 29 in Q1 2019.
- Funds reported $56.9M of Galmed Pharmaceuticals stock for Q2 2019, down 6.9% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q2 2019 and 2 closed out, a net change of +2 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2019 was Ibex Investors, an estimated $1.06M added.
- The largest Galmed Pharmaceuticals seller in Q2 2019 was UBS O'Connor, an estimated $503K sold.
Based on aggregated 13F filings for Q2 2019.